

Clarification and additional guidance on the prescribing of Schedule II Controlled Substances: On page 7 of the April 2005 *Action Report*, under Prescribing Controlled Substances, the board advised, “However, unless DEA changes its position, physicians must see their patients each time a prescription for a Schedule II drug is written.” The DEA is saying this is a misleading statement. The DEA is interested in preventing any form of refill for Schedule II prescriptions including prescriptions containing statements such as “do not fill until...” The amount prescribed and period for follow-up is not dictated by the DEA.

The following statement is to provide guidance and clarity for physicians who prescribe Schedule II Controlled Substances to their patients:

When prescribing Schedule II Controlled Substances to patients, the length of time and quantity of each Schedule II prescription should be based on the needs of each patient and must be within the standards of responsible prescribing. The physician must determine the appropriateness of each prescription written based on each patient’s medical history. However, it is only after a patient’s prior prescription is exhausted that the patient can receive a new prescription for the same Schedule II drug.